Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HR-positive / HER2-negative breast cancer, drawn from the whole corpus: 321 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Late recurrence: half of relapses occur after year 5 and no test reliably identifies who needs extended or intensified therapy.
Background: Circulating tumour DNA (ctDNA), Late recurrence, Tumour dormancy. Also on OnCo: Treatment journeys · Survivorship planner.
Adherence: a third of women stop adjuvant endocrine therapy early because of arthralgia, hot flushes, and sexual side effects.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Sequencing after CDK4/6: no head-to-head trials among oral SERDs, PI3K/AKT agents, everolimus combinations, and ADCs.
Does acting on ctDNA improve survival? SERENA-6 improved PFS; OS and patient-reported outcomes are unresolved, as the ODAC vote showed.
Palbociclib versus ribociclib versus abemaciclib: different survival results without a randomised comparison.
HER2-low scoring reproducibility at IHC 0/1+ determines T-DXd eligibility for millions of patients.
Invasive lobular carcinoma is under-represented in trials despite being 10-15% of cases.
Premenopausal women: whether chemotherapy's benefit in RxPONDER is simply ovarian suppression (NRG-BR009 / OFSET will answer).
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 124 changes by month →When this page itself was last checked or edited.
With imlunestrant, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
With abemaciclib, for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer
FDA approves gedatolisib with fulvestrant, with or without palbociclib, for HR-positive, HER2-negative locally advanced or metastatic breast cancer
FDA clearance: first digital-pathology-based risk stratification tool for early HR+/HER2- breast cancer
persevERA primary endpoint not met